BTLA-Binding Agents Modulate Immune Checkpoint Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively modulate immune checkpoint signals, particularly for autoimmune disorders and cancers, where dysregulation of coinhibitory molecules like BTLA leads to chronic inflammation and tissue damage.
Innovation Solution
Development of BTLA-binding agents comprising immunoglobulin heavy and light chain polypeptides that bind to BTLA without inhibiting its interaction with HVEM, potentially enhancing or inhibiting BTLA-mediated signaling to regulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If coinhibitory molecules like BTLA are blocked or knocked out to enhance immune response, then tumor-specific T cell expansion is improved, but autoimmune inflammation and tissue damage worsen
Solution Approach 1:
The patent uses engineered BTLA-binding agents (antibodies or binding proteins) as intermediaries to modulate the BTLA-HVEM interaction. These agents can either block the interaction to enhance anti-tumor immunity or agonize BTLA to suppress autoimmune responses, providing conditional control over the immune checkpoint pathway without complete knockout or constitutive blockade.
Solution Approach 2:
The invention enables dynamic modulation of BTLA signaling through different binding agents with varying mechanisms of action. Agonist antibodies can enhance BTLA-mediated suppression in autoimmune conditions, while antagonist antibodies can release suppression in cancer therapy, allowing the system to adapt to different pathological states rather than maintaining a fixed blocked or knockout state.
2Object-affected harmful factors
If BTLA is completely blocked to suppress autoreactive T cells, then autoimmune disease activity is reduced, but natural HVEM-BTLA immune regulation is interfered with
Solution Approach 1:
The patent employs binding agents with engineered specificities that can target BTLA in a localized or selective manner. Different binding agents can be designed to preferentially bind BTLA in specific tissue contexts or under specific activation states, allowing suppression of autoreactive cells in autoimmune tissues while preserving natural HVEM-BTLA regulation in other contexts.
Solution Approach 2:
The invention utilizes binding agents that can modulate BTLA function by changing its conformational state or signaling parameters rather than complete blockade. Agonist antibodies induce BTLA activation to enhance suppressive signals, while antagonist antibodies partially block with tunable affinity, allowing fine-tuned control that preserves aspects of natural regulation while achieving therapeutic suppression.
3Productivity
If coinhibitory molecule pathways are pharmacologically blocked, then T cell proliferation and effector functions are enhanced, but immunologic tolerance to self is compromised
Solution Approach 1:
The patent enables periodic or pulsed administration of BTLA-binding agents to achieve temporary enhancement of T cell proliferation followed by restoration of tolerance mechanisms. This allows the immune system to mount enhanced anti-tumor responses in treatment cycles while maintaining immunologic tolerance between cycles, avoiding constitutive disruption of self-tolerance.
Data Source
AI summary
A BTLA-binding agent and immunoglobulin heavy chain and light chain polypeptides of the binding agent, as well as methods of using the BTLA-binding agent to treat a disorder or disease that is responsive to BTLA agonism, such as an autoimmune or inflammatory disease.